Ponatinib Active Not Recruiting Phase 2 Trials for Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01746836Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib